Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 02, 2025 07:40 ET | Source: Emergent BioSolutions

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

GAITHERSBURG, Md., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $30 million contract modification from the Biomedical Advanced Research...
August 29, 2025 08:05 ET | Source: Emergent BioSolutions

Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day

Pro Football Hall of Famer and Ready to Rescue campaign spokesperson, Emmitt Smith, and Release Recovery Founder/CEO, Zac Clark, plan to visit several U.S. college campuses to educate on opioid...
August 27, 2025 08:01 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following...
August 21, 2025 08:45 ET | Source: Emergent BioSolutions

Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™

GAITHERSBURG, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) -- As opioid emergencies continue to be the leading cause of accidental death in the United States,1 Emergent BioSolutions (NYSE: EBS) is teaming up...
August 06, 2025 16:15 ET | Source: Emergent BioSolutions

Emergent BioSolutions Reports Second Quarter 2025 Financial Results

Second Quarter 2025 Total Revenues of $140.9 million, above Q2 guidance by $21 millionSecond Quarter 2025 Net Loss of $12.0 million and Net Loss Margin of (9)%, an improvement of 96% and 10,200 bps,...
July 28, 2025 08:50 ET | Source: Emergent BioSolutions

New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox

GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the publication of a comprehensive review article, "Brincidofovir in the Era of Mpox," in...
July 28, 2025 08:50 ET | Source: Emergent BioSolutions

Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives

GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announces its recognition of the U.S. House of Representatives for adding over-the-counter (OTC)...
July 15, 2025 07:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025

GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, August 6, 2025, at 5:00 pm eastern time to discuss the financial...
July 08, 2025 16:45 ET | Source: Emergent BioSolutions

Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts

GAITHERSBURG, Md., July 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016® [Vaccinia Immune Globulin...
July 02, 2025 16:05 ET | Source: Emergent BioSolutions

Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate

GAITHERSBURG, Md., July 02, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the expansion of its proprietary NARCANDirect® online distribution network to include...